OBJECTIVE: @entity4089 in @entity1 may be associated with a high prevalence of @entity28 but the nature of this link is poorly defined. The aim of this study was to establish the relationship between @entity4089 and body weight in @entity1 with @entity4090 -secreting @entity5 . DESIGN: We conducted a retrospective study of @entity2013 @entity1 treated at the Endocrine Institute of the @entity9604 Aviv Medical Center, Israel, during the period 1989-1996. @entity1 with clinically non-functioning pituitary macroadenomas (NFA) served as the control group. Data on demographic parameters, body weight before and during treatment, clinical presentation including history of weight fluctuations, @entity5 size as measured by computed tomography or magnetic resonance imaging, modalities and response to treatment, and pituitary function before and during treatment were recorded from medical files. @entity1 : Forty-two @entity1 with @entity2013 ( @entity2013 ) and 36 @entity1 with clinically non-functioning macroadenomas (NFA) comprised the study population. RESULTS: Mean weight was 93 +/- 3.4 kg and 78 +/- 2.7 kg in male @entity1 with @entity2013 and NFA respectively (P = 0.0007). Recent @entity1017 (8 to 22 kg) was a presenting symptom in 13 @entity2013 @entity1 , whereas only one NFA @entity1 had this clinical presentation (P = 0.001). Seventeen @entity2013 @entity1 lost weight (mean change -8.3 +/- 1.5 kg, range -2-28 kg), during @entity4090 lowering therapy, 11 of whom had entirely normalized @entity4090 levels. Fourteen of the 18 @entity1 who did not lose weight still had elevated @entity4090 levels (P = 0.01). @entity353 in @entity1 with @entity2013 could not be attributed to altered pituitary function nor to compression of the third ventricle. In contrast to @entity2013 , no significant @entity353 was observed in NFA @entity1 . CONCLUSION: Weight gain and elevated body weight are frequently associated with @entity2013 regardless of a mass effect on the hypothalamus or pituitary function. In this series, @entity353 was recorded in 70% of @entity2013 @entity1 and in 90% of male @entity1 who normalized their @entity4090 levels. We propose the inclusion of @entity4089 in the differential diagnosis of endocrine @entity28 and @entity1017 .

Increased body weight associated with @entity4090 secreting pituitary adenomas: @entity353 with normalization of XXXX levels.

@entity1 :: ('9606', 'Species') :: ['humans', 'patients', 'Patients', 'PATIENTS', 'patient'] @entity4089 :: ('MESH:D006966', 'Disease') :: ['hyperprolactinaemia', 'Hyperprolactinaemia'] @entity2013 :: ('MESH:D015175', 'Disease') :: ['prolactinoma', 'prolactinomas', 'PR'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss', 'Weight loss'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['pituitary tumours', 'tumour'] @entity9604 :: ('2120', 'Gene') :: ['Tel'] @entity4090 :: ('5617', 'Gene') :: ['prolactin'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain']
@entity4090 :: (5617,Gene) :: ['prolactin']
